These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 23485622)

  • 1. Analysis of early hypertension and clinical outcome with bevacizumab: results from seven phase III studies.
    Hurwitz HI; Douglas PS; Middleton JP; Sledge GW; Johnson DH; Reardon DA; Chen D; Rosen O
    Oncologist; 2013; 18(3):273-80. PubMed ID: 23485622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigating the potential of bevacizumab in other indications: metastatic renal cell, non-small cell lung, pancreatic and breast cancer.
    de Gramont A; Van Cutsem E
    Oncology; 2005; 69 Suppl 3():46-56. PubMed ID: 16301835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of bevacizumab-induced hypertension and outcomes of metastatic colorectal cancer patients treated with bevacizumab: a systematic review and meta-analysis.
    Cai J; Ma H; Huang F; Zhu D; Bi J; Ke Y; Zhang T
    World J Surg Oncol; 2013 Nov; 11():306. PubMed ID: 24283603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599.
    Dahlberg SE; Sandler AB; Brahmer JR; Schiller JH; Johnson DH
    J Clin Oncol; 2010 Feb; 28(6):949-54. PubMed ID: 20085937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib.
    Rini BI; Cohen DP; Lu DR; Chen I; Hariharan S; Gore ME; Figlin RA; Baum MS; Motzer RJ
    J Natl Cancer Inst; 2011 May; 103(9):763-73. PubMed ID: 21527770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
    Grünwald V; Lin X; Kalanovic D; Simantov R
    Eur Urol; 2016 Dec; 70(6):1006-1015. PubMed ID: 27238653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bevacizumab-induced hypertension: pathogenesis and management.
    Syrigos KN; Karapanagiotou E; Boura P; Manegold C; Harrington K
    BioDrugs; 2011 Jun; 25(3):159-69. PubMed ID: 21627340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypertension as a predictive marker for bevacizumab in metastatic breast cancer: results from a retrospective matched-pair analysis.
    Gampenrieder SP; Romeder F; Muß C; Pircher M; Ressler S; Rinnerthaler G; Bartsch R; Sattlberger C; Mlineritsch B; Greil R
    Anticancer Res; 2014 Jan; 34(1):227-33. PubMed ID: 24403467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer.
    Wagner AD; Thomssen C; Haerting J; Unverzagt S
    Cochrane Database Syst Rev; 2012 Jul; (7):CD008941. PubMed ID: 22786517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypertension as predictive factor for bevacizumab-containing first-line therapy in metastatic breast and colorectal cancer in BRECOL (GEICAM/2011-04) study.
    Rodríguez-Lescure Á; Gallego J; Garcia-Alfonso P; Massuti B; Márquez R; Calvo L; Sánchez-Rovira P; Antón A; Chacón JI; Ciruelos E; Ponce JJ; Santaballa A; Valladares-Ayerbes M; Dueñas MR; Alonso V; Aparicio J; Encinas S; Robles L; Escudero MJ; Caballero R; Bezares S; de la Haba-Rodriguez J
    Clin Transl Oncol; 2024 Aug; 26(8):1896-1907. PubMed ID: 38578537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III).
    Schmoll HJ; Cunningham D; Sobrero A; Karapetis CS; Rougier P; Koski SL; Kocakova I; Bondarenko I; Bodoky G; Mainwaring P; Salazar R; Barker P; Mookerjee B; Robertson J; Van Cutsem E
    J Clin Oncol; 2012 Oct; 30(29):3588-95. PubMed ID: 22965961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive impact of circulating vascular endothelial growth factor in four phase III trials evaluating bevacizumab.
    Hegde PS; Jubb AM; Chen D; Li NF; Meng YG; Bernaards C; Elliott R; Scherer SJ; Chen DS
    Clin Cancer Res; 2013 Feb; 19(4):929-37. PubMed ID: 23169435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiangiogenic therapy for high-grade glioma.
    Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
    Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206.
    Rini BI; Halabi S; Rosenberg JE; Stadler WM; Vaena DA; Archer L; Atkins JN; Picus J; Czaykowski P; Dutcher J; Small EJ
    J Clin Oncol; 2010 May; 28(13):2137-43. PubMed ID: 20368558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of hypertension as a marker of bevacizumab efficacy.
    Ryanne Wu R; Lindenberg PA; Slack R; Noone AM; Marshall JL; He AR
    J Gastrointest Cancer; 2009; 40(3-4):101-8. PubMed ID: 19921473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors.
    Turnbull JD; Cobert J; Jaffe T; Harrison MR; George DJ; Armstrong AJ
    Clin Genitourin Cancer; 2013 Mar; 11(1):45-50. PubMed ID: 23041453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Early Adverse Events on Survival Outcomes of Patients with Metastatic Colorectal Cancer Treated with Ramucirumab.
    Lim HH; Hopkins AM; Rowland A; Yuen HY; Karapetis CS; Sorich MJ
    Target Oncol; 2019 Dec; 14(6):743-748. PubMed ID: 31676953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.
    Escudier B; Pluzanska A; Koralewski P; Ravaud A; Bracarda S; Szczylik C; Chevreau C; Filipek M; Melichar B; Bajetta E; Gorbunova V; Bay JO; Bodrogi I; Jagiello-Gruszfeld A; Moore N;
    Lancet; 2007 Dec; 370(9605):2103-11. PubMed ID: 18156031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation of hypertension and proteinuria with outcome in elderly bevacizumab-treated patients with metastatic colorectal cancer.
    Feliu J; Salud A; Safont MJ; García-Girón C; Aparicio J; Losa F; Bosch C; Escudero P; Casado E; Jorge M; Bohn U; Pérez-Carrión R; Carmona A; Custodio AB; Maurel J
    PLoS One; 2015; 10(1):e0116527. PubMed ID: 25602286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse cardiovascular events predict survival benefit in non-small lung cancer patients treated with bevacizumab.
    Koyama N
    Cancer Biomark; 2014; 14(4):259-65. PubMed ID: 24934369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.